Avacta Group PLC (AVCT) - Cash Flow Conversion Efficiency

Latest as of June 2025: -93.806x

Based on the latest financial reports, Avacta Group PLC (AVCT) has a cash flow conversion efficiency ratio of -93.806x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-13.51 Million ≈ $-1.64K USD) by net assets (GBX144.00K ≈ $17.52 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See AVCT cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Avacta Group PLC - Cash Flow Conversion Efficiency Trend (2001–2024)

This chart illustrates how Avacta Group PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Avacta Group PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Avacta Group PLC ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
GLOW LIFETECH CORP.
F:9DO
0.054x
Advance Information Marketing Bhd
KLSE:0122
0.010x
SPOBAG AG
F:SBE
N/A
AGS Transact Technologies Limited
NSE:AGSTRA
0.198x
ARC Funds Ltd
AU:ARC
-0.304x
Octopus Titan VCT
LSE:OTV2
-0.015x
New Concept Energy Inc
NYSE MKT:GBR
-0.015x
The House of Agriculture Spiroy S.A.
AT:SPIR
0.757x

Annual Cash Flow Conversion Efficiency for Avacta Group PLC (2001–2024)

The table below shows the annual cash flow conversion efficiency of Avacta Group PLC from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see AVCT stock market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 GBX9.28 Million
≈ $1.13K
GBX-23.60 Million
≈ $-2.87K
-2.543x -272.78%
2023-12-31 GBX21.80 Million
≈ $2.65K
GBX-14.87 Million
≈ $-1.81K
-0.682x +23.47%
2022-12-31 GBX18.44 Million
≈ $2.24K
GBX-16.43 Million
≈ $-2.00K
-0.891x -79.15%
2021-12-31 GBX41.22 Million
≈ $5.02K
GBX-20.51 Million
≈ $-2.49K
-0.497x -189.48%
2020-12-31 GBX61.93 Million
≈ $7.53K
GBX-10.64 Million
≈ $-1.29K
-0.172x +32.71%
2018-07-31 GBX21.41 Million
≈ $2.61K
GBX-5.47 Million
≈ $-665.30
-0.255x -79.97%
2017-07-31 GBX29.89 Million
≈ $3.64K
GBX-4.24 Million
≈ $-516.01
-0.142x -20.19%
2016-07-31 GBX35.86 Million
≈ $4.36K
GBX-4.23 Million
≈ $-515.03
-0.118x +10.19%
2015-07-31 GBX19.13 Million
≈ $2.33K
GBX-2.52 Million
≈ $-306.00
-0.131x -352.36%
2014-07-31 GBX28.84 Million
≈ $3.51K
GBX-838.00K
≈ $-101.96
-0.029x +67.18%
2013-07-31 GBX15.55 Million
≈ $1.89K
GBX-1.38 Million
≈ $-167.54
-0.089x -111.16%
2012-07-31 GBX16.96 Million
≈ $2.06K
GBX-711.00K
≈ $-86.51
-0.042x +19.54%
2011-07-31 GBX11.44 Million
≈ $1.39K
GBX-596.00K
≈ $-72.52
-0.052x +70.16%
2010-07-31 GBX9.97 Million
≈ $1.21K
GBX-1.74 Million
≈ $-211.83
-0.175x +48.24%
2009-07-31 GBX8.30 Million
≈ $1.01K
GBX-2.80 Million
≈ $-340.56
-0.337x -26.84%
2008-07-31 GBX4.87 Million
≈ $592.42
GBX-1.29 Million
≈ $-157.56
-0.266x +44.06%
2007-07-31 GBX2.63 Million
≈ $319.87
GBX-1.25 Million
≈ $-152.09
-0.475x +95.21%
2006-04-30 GBX14.00K
≈ $1.70
GBX-139.00K
≈ $-16.91
-9.929x -148.21%
2005-04-30 GBX21.00K
≈ $2.56
GBX-84.00K
≈ $-10.22
-4.000x -916.22%
2004-04-30 GBX1.03 Million
≈ $125.81
GBX-407.00K
≈ $-49.52
-0.394x -315.55%
2003-04-30 GBX-230.00K
≈ $-27.98
GBX-42.00K
≈ $-5.11
0.183x -8.87%
2002-04-30 GBX-529.00K
≈ $-64.36
GBX-106.00K
≈ $-12.90
0.200x -47.29%
2001-04-30 GBX-363.00K
≈ $-44.17
GBX-138.00K
≈ $-16.79
0.380x --

About Avacta Group PLC

LSE:AVCT UK Biotechnology
Market Cap
$3.91 Million
GBX32.17 Billion GBX
Market Cap Rank
#29015 Global
#528 in UK
Share Price
GBX73.50
Change (1 day)
+0.00%
52-Week Range
GBX30.50 - GBX89.00
All Time High
GBX274.91
About

Avacta Group Plc, together with its subsidiaries, engages in the development of cancer therapies in the United Kingdom, South Korea, and internationally. Its lead product candidate is AVA6000, a peptide drug conjugate form of doxorubicin, which is an approved cancer drug with known severe toxicities. The company is developing AVA6103, a peptide drug conjugate technology designed to deliver exatec… Read more